Minerva Endocrinology, published by EDIZIONI MINERVA MEDICA in Italy, serves as a pivotal platform for advancing knowledge in the field of endocrinology, diabetes, and metabolism. With its ISSN 2724-6507 and E-ISSN 2724-6116, the journal has rapidly established a reputable position in academia, achieving impressive rankings such as Q3 in both Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. This enables Minerva Endocrinology to attract a diverse readership, including researchers, healthcare professionals, and students committed to understanding the complexities of endocrine disorders. With annual publications covering breakthroughs and innovative research covering converged years from 2021 to 2024, the journal is devoted to facilitating the dissemination of high-quality studies that advance clinical and laboratory practices. Despite its >Open Access< status, the journal encourages submissions that reflect rigorous scientific inquiry and uphold the highest standards of scholarship, thereby enhancing its role as a significant contributor to the field of internal medicine and endocrinology.

Revista Portuguesa de Endocrinologia Diabetes e Metabolismo is a pivotal journal dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Published by the esteemed SOC PORTUGUESA ENDOCRINOLOGIA, DIABETES & METABOLISMO-SPEDM, this journal serves as a platform for the dissemination of high-quality research, clinical studies, and innovative practices within these related disciplines. With a commitment to providing insightful and impactful content, the journal aims to foster knowledge sharing among researchers, healthcare professionals, and students interested in the latest developments in endocrine disorders and metabolic diseases. Although currently not open access, the journal's comprehensive approach and rigorous peer-review process ensure that it remains a respected source of information for its readers in Portugal and beyond. With its address rooted in the heart of Lisbon, the Revista Portuguesa de Endocrinologia Diabetes e Metabolismo plays a vital role in enhancing the understanding and treatment of endocrine and metabolic conditions in the modern healthcare landscape.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES is a distinguished journal published by GEORG THIEME VERLAG KG, dedicated to advancing research and understanding in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 0947-7349 and an E-ISSN of 1439-3646, this journal serves as a critical platform for disseminating high-quality research findings, reviews, and clinical studies from 1983 to 2024. The journal holds an impactful position within its respective categories, notably achieving Q3 in Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as per the 2023 category quartiles. Additionally, it ranks in the 57th and 46th percentiles in the Scopus rankings for Internal Medicine and Endocrinology, Diabetes and Metabolism, respectively. Though not an open-access publication, the journal caters to a global audience of researchers, professionals, and students, facilitating knowledge exchange and fostering collaboration within this vital area of medical science.

Journal of the Endocrine Society, published by the ENDOCRINE SOC, stands as a prominent platform for disseminating significant research and findings within the field of endocrinology, diabetes, and metabolism. Established as an Open Access journal since 2017, it aims to increase the visibility and accessibility of vital scholarly contributions, allowing researchers and professionals from various backgrounds to engage with the latest insights in this rapidly evolving discipline. With an impressive Q2 ranking in Endocrinology, Diabetes and Metabolism, the journal is recognized for its impact, ranking #100 out of 244 in Scopus, highlighting its role in advancing scientific knowledge and fostering innovation. The journal, based in the United States at 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036, continues to enrich the academic landscape by converging state-of-the-art research and clinical applications through its publication cycle from 2017 to 2024. Researchers, students, and healthcare professionals are encouraged to explore this essential resource to stay at the forefront of endocrinological advancements.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

The Turkish Journal of Endocrinology and Metabolism, published by AVES, is a prominent platform dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. As an Open Access journal since 2002, it provides unrestricted access to its content, fostering a global exchange of knowledge among researchers, clinicians, and students. Operating from Turkey, this journal plays a crucial role in disseminating innovative findings related to endocrine disorders and metabolic diseases. While its current Q4 quartile rankings in both Endocrinology and Internal Medicine underscore areas for growth, they also signify the journal’s commitment to enhancing its impact within these disciplines. The journal emphasizes the development of locally relevant research while encouraging international contributions, thus bridging gaps in global health discourse. Engage with cutting-edge research that shapes clinical practices and informs public health policies by submitting your work or exploring the journal’s vast archive from 2009 to 2023.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, published by the Endocrine Society, stands as a premier academic journal within the field of endocrinology, diabetes, and metabolism. With a legacy spanning from 1941 to 2024, this journal is distinguished by its significant impact factor, ranking in the Q1 category across multiple related disciplines including biochemistry, clinical biochemistry, and medicine. This esteemed journal, ISSN 0021-972X and E-ISSN 1945-7197, is backed by rigorous peer review, ensuring the publication of high-quality research that contributes to the advancement of clinical practices and scientific knowledge. With a commendable Scopus ranking, positioned in the top percentile of multiple categories, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM serves as an essential resource for researchers, professionals, and students who seek to stay informed about the latest findings and innovations in endocrine research. The journal enriches the existing body of knowledge and fosters discussion among scholars and practitioners alike, solidifying its crucial role in the ongoing discourse in endocrinology and metabolic health.

Expert Review of Endocrinology & Metabolism is a premier journal dedicated to advancing the field of endocrinology and metabolism, published by Routledge Journals, Taylor & Francis Ltd, in the United Kingdom. With a robust focus on the latest research, innovative treatments, and clinical practices, this journal serves as an essential resource for healthcare professionals, researchers, and students seeking to stay abreast of developments in diabetes, obesity, thyroid disorders, and other endocrine-related conditions. Achieving a commendable Q2 status in Endocrinology, Diabetes, and Metabolism in the 2023 ranking, Expert Review of Endocrinology & Metabolism holds strong standing with an impressive Scopus rank, placing it at the 53rd percentile among its peers. The journal embraces a comprehensive approach, offering critical reviews, original research articles, and insights on emerging trends and technologies in the field. Although not an open-access journal, it provides extensive access options for subscribers and institutions, encouraging ease of dissemination and academic engagement. Through its commitment to high-quality content, Expert Review of Endocrinology & Metabolism remains pivotal for professionals aiming to enhance their understanding and practice in this vital area of medicine.

Frontiers in Endocrinology, published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to the advancement of research in the fields of endocrinology, diabetes, and metabolism. Established in 2010, this journal has consistently demonstrated its academic excellence, achieving a prominent Q1 quartile ranking in its category as of 2023, and a commendable Scopus rank of #96 out of 244, placing it within the 60th percentile. The journal is committed to disseminating high-quality research that encompasses a wide range of topics within endocrinology, catering to the needs of a diverse audience that includes researchers, medical professionals, and students alike. With the critical goal of fostering knowledge-sharing and collaboration within the scientific community, Frontiers in Endocrinology is an invaluable resource for anyone looking to stay updated on the latest advancements and insights in endocrinology. It operates under a robust open-access model, ensuring that groundbreaking research is accessible to all, thereby driving innovation and progress in this essential field.

Current Opinion in Endocrinology, Diabetes and Obesity, published by LIPPINCOTT WILLIAMS & WILKINS, offers a critical analysis of the latest advancements and trends in the fields of endocrinology, diabetes, and obesity. With an ISSN of 1752-296X and an E-ISSN of 1752-2978, this esteemed journal provides an authoritative platform for researchers, clinicians, and healthcare professionals to stay updated on emerging research and clinical practices. Renowned for its impactful contributions, the journal holds notable rankings, including Q2 in Endocrinology and Diabetes & Metabolism, as well as a commendable Q1 in Internal Medicine, reflecting its significance in the academic community. Although currently not an open access publication, articles published from 2007 to 2024 continually enrich the discourse on pressing health issues related to endocrinology and metabolic disorders. By fostering a comprehensive understanding of the complexities within these interconnected fields, it serves as an essential resource for any professional or student engaged in health science research.